Microcore Biology: Theo Ronnie Capsules Approved for Clinical Trials

February 9, micro-core biological announcement, the company recently received the State Drug Administration issued IND (new drug clinical trial application) "receiving notice."
product name is Theo Ronnie Capsule.
is a new chemical structure with global patent protection designed and developed by the company, which is a multi-target multi-path selective kinase inhibitor.
is a small molecule anti-tumor original innovative drug that selectively inhibits multiple kinase targets such as Aorora B, CSF1R, and VEGFR/PDGFR/c-Kit.
by inhibiting cell cycle regulation kinase Aurora B, Therononi can inhibit the cycle process of tumor cells and reduce tumor proliferation activity; New blood vessels form, thereby reducing the blood supply and growth of tumors, and by inhibiting CSF1R associated with immune cell proliferation and activity, Theoroni can inhibit the growth of local immunosuppressive cells in tumors, thereby improving the body's immune surveillance and immune removal of tumors.
, Theroni realized the anti-tumor effect of multi-path mechanism by inhibiting the three active mechanisms of tumor cells with silk division, inhibiting tumor angiogenesis and regulating tumor immunological microenvironment, so as to play a comprehensive anti-tumor effect and have better animal llermic activity and good safety than similar mechanism drugs.
Phase II clinical study of platinum-difficult/platinum-resistant recurrence ovarian cancer with combined chemotherapy showed good patient tolerance, with the main side effects associated with the mechanism of action and no heart-related toxicity observed.
the effectiveness of Theuroni's single drug has been confirmed in patients with small cell lung cancer and platinum-resistant ovarian cancer.
As an original innovative drug that treats major diseases that pose a serious threat to life and health and has a clear clinical advantage over existing treatments, theo Ronnie was included in the "Breakthrough Treatment Variety" by CDE on December 25 last year, as detailed in the Company's "Voluntary Disclosure of the Company's Product Inclusion in The Proposed Breakthrough Treatment Varieties" on the Shanghai Stock Exchange website on December 19, 2020 (Notice No.